Related Experiment Video

Updated: May 3, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

14.4K

The optimal treatment of STEMI: new pharmacological and device approaches

M R Movahed1

  • 1CareMore Health Care Arizona, Division of Cardiology The Southern Arizona VA health Care System Tucson, Arizona and Division of Cardiology University of Arizona, Tucson, AZ, USA - rmova@aol.com.

Panminerva Medica
|January 18, 2014
PubMed

Insights

Acute ST elevation myocardial infarction (STEMI) treatments have improved, leading to reduced mortality. This review covers recent advancements in pharmacological and device therapies for STEMI patients.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Medical Research

Background:

  • Cardiovascular disease is the primary global cause of death.
  • Acute ST elevation myocardial infarction (STEMI) significantly contributes to mortality.
  • Recent data indicate a decline in STEMI-related deaths over the past ten years.

Purpose of the Study:

  • To review emerging pharmacological treatments for STEMI.
  • To discuss novel device-based therapies for STEMI management.
  • To provide an overview of recent advancements in STEMI care.

Main Methods:

  • Literature review of recent epidemiological studies.
  • Analysis of pharmacological advancements in STEMI treatment.
  • Evaluation of new device technologies for STEMI.

Main Results:

  • STEMI mortality has decreased in the last decade.
  • New drug therapies have shown efficacy in STEMI management.
  • Innovative devices have improved STEMI patient outcomes.

Conclusions:

  • Advancements in pharmacological and device therapies are key to reduced STEMI mortality.
  • Continued research into new treatments is crucial for further improving STEMI patient survival.
  • This review highlights the evolving landscape of STEMI treatment strategies.

More Related Videos

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

2.7K
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

4.1K

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
522
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741